Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

Freitas, Cláudia; Jacob, Maria; Tavares, N.; Cruz‐Martins, Natália; Souto-Moura, Conceição; Araújo, David; Bastos, Hélder Novais; Santos, Vanessa; Fernandes, Gabriela; Magalhães, Adriana; Hespanhol, Venceslau; Queiroga, Henrique

doi:10.1097/cad.0000000000001060

Cited by 7 publications

(5 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of them, 19 were retrospective cohort studies, 21 - 24 , 31 , 32 , 35 , 37 - 46 , 48 and nine were prospective cohort studies. 17 - 20 , 30 , 33 , 34 , 36 , 47 Publication years of the studies ranged from 2010 to 2021, and the sample sizes varied from 24 to 1,745 LC patients. One publication was treated as two separate studies due to its coverage of two different cohorts (operative and nonoperative) and separate reporting of hazard ratios (HRs).…”

Section: Resultsmentioning

confidence: 99%

“… 49 Studies showed that inflammatory markers, such as the neutrophil/lymphocyte and platelet/lymphocyte ratios, have shown correlations with poor prognosis in certain solid malignancies. 7 , 15 The modified Glasgow Prognostic Score takes into account both serum C-reactive protein (CRP) and albumin levels in clinical samples, 33 , 50 and reflects both the inflammatory and nutritional status of patients. 51 Production of CRP, an acute-phase protein primarily produced by hepatocytes, is triggered by inflammation, tissue injury, and infection.…”

Section: Discussionmentioning

confidence: 99%

“…The details of the 28 included studies [17][18][19][20][21][22][23][24][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] [21][22][23][24]31,32,35,[37][38][39][40][41][42][43][44][45][46]48 and nine were prospective cohort studies. [17][18][19][20]30,33,34,…”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis

Min,

Li,

Chen

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

Background & Objective: Previous studies have suggested that the modified Glasgow Prognostic Score (mGPS) could be a potential biomarker for lung cancer (LC). However, the association between mGPS and overall survival (OS) or progression-free survival (PFS) in lung cancer patients remains unclear. The purpose of our study was to investigate possible correlation between mGPS and OS or PFS in LC patients. Methods: An extensive search of PubMed, Cochrane Library, EMbase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Trip Database, Worldwide Science, and Google Scholar databases was done for relevant articles, published prior to May 30, 2021, that report correlation between mGPS and OS or PFS in LC patients. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used as the main parameters for evaluation. Results: A total of 28 studies involving 9,748 lung cancer patients were analysed. The pooled analysis revealed that elevated mGPS (≥ 0) was associated with poor OS (HR=1.54; 95% CI, 1.32-1.77) and PFS (HR=1.49; 95% CI, 1.17-1.82). Furthermore, a significant correlation between mGPS (1 or 2) and OS was observed. However, no significant correlation was found between mGPS (1 or 2) and PFS. Subgroup analysis based on ethnicity demonstrated that mGPS ≥ 0 was associated with worse OS compared to mGPS=0 in both Asian (HR=1.46; 95% CI, 1.04-1.89; p<0.05) and Caucasian (HR=1.64; 95% CI, 1.35-1.94; p<0.05) cohorts of LC patients. Conclusions: Our results demonstrate that positive mGPS is associated with poor survival results. Therefore, mGPS may be used as a biomarker for predicting prognosis in LC patients. doi: https://doi.org/10.12669/pjms.40.3.8397 How to cite this: Min Y, Li X, Chen H, Xu Y, Lan G. Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis. Pak J Med Sci. 2024;40(3):---------. doi: https://doi.org/10.12669/pjms.40.3.8397 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis

Min,

Li,

Chen

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…The full texts of the remaining 23 articles were reviewed. Finally, 14 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 studies including 1164 patients were eligible (Figure 1 ). Among them, most studies considered mGPS as categorical variable in multivariate analysis, while Takamori et al 27 used mGPS as a continuous variable, and therefore this study was not enrolled in meta‐analysis.…”

Section: Resultsmentioning

confidence: 99%

A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer

Zhang

Chen

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background The association between Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) and clinical outcomes in patients receiving immune checkpoint inhibitors (ICIs) remains controversial. Thus, this meta‐analysis aimed to examine the prognostic performance of GPS and mGPS in patients treated with ICIs. Methods Eligible studies were retrieved from searches of EMBASE, PubMed, Web of Science, and Cochrane Library until July 2021. The hazard ratio (HR) and 95% confidence intervals (CIs) were pooled by using fixed‐effect or random‐effects model to evaluate the influence of GPS/mGPS on overall survival (OS) and progression‐free survival (PFS). Results A total of 1164 patients were included. Overall, mGPS score of 2 and 1 were related to inferior OS ( p < 0.001) and PFS ( p < 0.001). Subgroup analyses showed no significant association between mGPS score of 1 and OS in patients with non‐small cell lung cancer (NSCLC), while this score was significantly associated with poor PFS in patients with NSCLC and head and neck squamous cell carcinoma. Higher GPS (score of 1 or 2) were associated with poor clinical outcomes (OS: p < 0.001; PFS: p = 0.036). Subgroup analysis showed high GPS levels were linked to worse OS in patients with NSCLC and gastric cancer, but not for PFS in these patients. Regarding test time point, GPS was related to worse OS and PFS in pre‐treatment GPS group, but not in post‐treatment GPS group. Conclusion GPS and mGPS showed great potential to predict survival in patients treated with ICIs. Large and perspective trial are warranted to further validate these findings.

show abstract

“…Previous studies have shown that mGPS has a significant relationship with survival in NSCLC patients. Some of these studies were conducted in patients who underwent surgery in the early stage [ 21 ], and some in advanced patients [ 22 ]. In many studies, mGPS was generally examined before treatment, but there are also studies investigating the efficacy of treatment with mGPS after treatment [ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer

Erciyestepe,

Selvi,

Dinç Sonuşen

et al. 2023

Med Princ Pract

View full text Add to dashboard Cite

Objective: In studies conducted on non-small cell lung cancer (NSCLC) patients, many factors such as age, stage, weight loss, lymph node, and pleural involvement have been shown to affect survival. On the other hand, systemic inflammation plays a critical role in proliferation, migration, invasion, and metastasis. Inflammation and nutrition-based prognostic scores are reported to be associated with survival in patients with NSCLC. The aim of our study is to show the effects of these scores on survival and disease progression in NSCLC patients. Subjects and Methods: Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) values in 102 patients with stage 1,2 and 3A NSCLC were analyzed retrospectively. Results: NLR (p < 0.001), PLR (p = 0.001), PNI (p < 0.001), and mGPS (p = 0.001) variables showed a statistically significant difference according to mortality groups. NLR and PLR values were higher in exitus patients. However, PNI values were higher in surviving patients. NLR (p < 0.001), PLR (p = 0.004), PNI (p = 0.001), and mGPS (p = 0.015) variables showed a statistically significant difference in terms of locoregional recurrence. PNI (p = 0.001) and mGPS (p = 0.001) in terms of distant metastasis development during follow-up and treatment, showed a statistically significant difference. Conclusion: NLR, PLR, PNI, and mGPS are easily accessible and non-invasive parameters and provide predictive information about survival and disease course. We showed the effect of these parameters on the prognosis.

show abstract

Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

Cited by 7 publications

References 66 publications

Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis

Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis

A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer

Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About